{"brief_title": "Effect of the Atazanavir (ATV) 150L Mutation on Subsequent Treatment Response in HIV Infected Subjects", "brief_summary": "This study will compare the response of subjects who failed a first-line ATV-containing regimen and who have the 150L-containing virus to subsequent protease inhibitor (PI)-containing therapy with that of a cohort who has failed a first-line reverse transcriptase inhibitor (NNRTI), and is subsequently receiving PI-containing therapy.", "condition": ["HIV Infection"], "intervention_type": ["Drug", "Drug"], "intervention_name": ["LPV/RTV + 2NRTIs", "LPV/RTV + 2NRTIs"], "description": ["Tablets, Oral, Variable, Twice daily, 48 weeks.", "Tablets, Oral, Variable, Twice daily, 48 weeks."], "arm_group_label": ["A1", "A2"], "study_pop": "\n      ", "sampling_method": "Non-Probability Sample", "criteria": "Inclusion Criteria: - Currently on a first-line antiretroviral regimen containing ATV with a confirmed rebound and a genotype that verifies the presence of an 150L mutation OR on a first-line regimen containing an NNRTI and PI-naive, with a confirmed rebound Exclusion Criteria: - Women of child bearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 8 weeks after the study. - Women who are pregnant or breastfeeding. - A life expectancy of <12 months. - Presence of a newly diagnosed HIV-related opportunistic infection or any other medical condition requiring acute therapy at the time of enrollment. - Active alcohol or substance abuse sufficient, in the investigator's opinion, to prevent adequate adherence to study therapy or to increase the risk of developing pancreatitis or chemical hepatitis.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "Treatment Experienced", "mesh_term": ["HIV Infections", "Atazanavir Sulfate"], "id": "NCT00096746"}